EGFR and non-small cell lung carcinoma: A recent study performed by the CLICaP consortium, for example, analyzed the genomic landscape of primary resistance to Osimertinib among Hispanic patients with EGFR-mutant non-small cell lung cancer, showing that specific findings such as commutations, and the presence of the mutations EGFR p.T790M and p.L858R are associated with therapeutic responses and patient outcomes (72).